1022P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)Jonathan W. Riess, T. Seiwert, V. Villaflor et al.|Annals of Oncology|2024Cited by 3
1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)Jonathan W. Riess, Ezra E.W. Cohen, James Spicer et al.|Annals of Oncology|2023Cited by 2